Vascular Closure Devices Market Size, Share, and Growth Forecast 2026 - 2033

The global vascular closure devices market size is estimated to reach US$1.8 billion in 2026 and is projected to grow to US$2.7 billion by 2033, expanding at a CAGR of 5.8% from 2026 to 2033, driven by the rising number of catheter-based cardiovascular procedures, including coronary angiography, percutaneous coronary intervention (PCI), and peripheral vascular interventions. The increasing prevalence of cardiovascular diseases, supported by the growing aging population, is accelerating demand for effective vascular access closure solutions.

According to the American Heart Association (AHA), cardiovascular disease remains a major global health burden, leading to increased adoption of minimally invasive procedures. Additionally, the shift toward same-day discharge protocols and faster patient recovery is encouraging hospitals to adopt advanced vascular closure devices that provide rapid hemostasis, reduce complications, and improve procedural efficiency.

Driver - Rising Global Burden of Cardiovascular Disease and Increasing Catheter-Based Interventions

The vascular closure devices market is primarily driven by the increasing prevalence of cardiovascular diseases (CVDs) and the growing number of catheter-based diagnostic and therapeutic procedures worldwide. According to the World Health Organization (WHO), cardiovascular diseases remain the leading cause of death globally, creating sustained demand for coronary angiography, percutaneous coronary intervention (PCI), transcatheter aortic valve replacement (TAVR), electrophysiology procedures, and peripheral vascular interventions.

As procedural volumes continue to increase, healthcare providers are adopting vascular closure devices to achieve rapid hemostasis, reduce access-site bleeding complications, shorten time to ambulation, and improve patient comfort. Compared with conventional manual compression, these devices enhance catheterization laboratory efficiency by reducing recovery time and enabling faster patient turnover. The continued expansion of minimally invasive cardiovascular procedures across hospitals and ambulatory care settings is expected to support long-term demand for advanced vascular closure technologies throughout the forecast period.

Restraint - Risk of Access-Site Complications and Patient Selection Challenges

Despite their clinical advantages, vascular closure devices are associated with certain procedural risks that may limit broader adoption. Potential complications, including bleeding, hematoma, pseudoaneurysm, arterial occlusion, infection, vessel stenosis, and device failure, remain important considerations during device selection.

Clinical outcomes largely depend on proper patient selection, vascular anatomy, and operator experience. Patients with severe peripheral artery disease, obesity, calcified arteries, or small vessel diameters may present greater procedural challenges, leading some physicians to prefer manual compression in complex cases. In addition, the successful deployment of active closure devices requires specialized training and procedural expertise, making physician experience an important factor influencing clinical outcomes and market adoption.

Opportunity - Expanding Electrophysiology and Structural Heart Procedures

The rapid growth of electrophysiology and structural heart interventions presents a significant opportunity for vascular closure device manufacturers. Rising prevalence of atrial fibrillation and other cardiac rhythm disorders has increased the number of catheter ablation procedures performed globally. These procedures frequently require multiple vascular access sites and larger sheath sizes, creating greater demand for reliable vascular closure solutions.

In addition, the increasing adoption of structural heart procedures such as transcatheter aortic valve replacement (TAVR) and transcatheter mitral valve interventions is driving the need for advanced large-bore vascular closure technologies. Manufacturers investing in innovative closure systems with improved safety profiles, enhanced deployment mechanisms, and compatibility with complex cardiovascular procedures are well positioned to capitalize on this expanding clinical segment.

Product Type Analysis

Active closure devices are expected to account for approximately 73.8% of the global vascular closure devices market in 2026, maintaining their leadership due to their superior ability to achieve rapid hemostasis, shorten time to ambulation, and reduce post-procedural recovery compared with passive closure methods. These devices, including suture-based, clip-based, and staple-based systems, are extensively used following coronary angiography, percutaneous coronary intervention (PCI), transcatheter aortic valve replacement (TAVR), and peripheral vascular interventions requiring reliable femoral artery closure.

Their ability to provide immediate mechanical vessel closure helps reduce access-site complications, improve catheterization laboratory workflow, and support same-day discharge protocols. Continuous technological advancements, including enhanced deployment mechanisms and improved safety profiles, have further strengthened physician confidence and clinical adoption. Although passive closure devices remain an important option for selected patient populations due to their lower cost and simpler operation, active closure devices continue to represent the preferred solution across high-volume hospitals and cardiac catheterization laboratories worldwide.

Application Analysis

Interventional cardiology is projected to dominate the application segment with approximately 46.7% market share in 2026, driven by the increasing number of coronary angiography and percutaneous coronary intervention (PCI) procedures performed globally. The growing prevalence of coronary artery disease, acute coronary syndrome, and other cardiovascular disorders has significantly increased the demand for catheter-based interventions requiring effective vascular access closure.

Vascular closure devices have become an integral component of post-procedural care by enabling rapid hemostasis, minimizing bleeding complications, reducing recovery time, and improving patient comfort. Their widespread use also supports greater operational efficiency by allowing faster patient turnover and optimizing catheterization laboratory capacity. Furthermore, the continued expansion of structural heart interventions and minimally invasive cardiovascular procedures is expected to sustain demand for vascular closure devices, while electrophysiology procedures are projected to register the fastest growth due to increasing atrial fibrillation ablation volumes and expanding adoption of advanced cardiac rhythm management therapies.

End-user Analysis

Hospitals are estimated to be the largest end-user segment, accounting for approximately 68.4% of the vascular closure devices market in 2026. Their dominance is attributed to the concentration of advanced cardiac catheterization laboratories, hybrid operating rooms, and specialized cardiovascular departments capable of performing high volumes of complex diagnostic and interventional procedures. Hospitals routinely perform coronary angiography, PCI, TAVR, peripheral vascular interventions, and electrophysiology procedures, creating consistent demand for both active and passive vascular closure devices.

In addition, the availability of experienced interventional cardiologists, vascular surgeons, and comprehensive emergency care infrastructure supports widespread adoption of advanced closure technologies. Large hospital networks also benefit from long-term procurement agreements with leading medical device manufacturers, ensuring a stable supply of vascular closure products. Although Ambulatory Surgical Centers (ASCs) are witnessing strong growth due to the increasing shift toward outpatient cardiovascular procedures and same-day discharge protocols, hospitals are expected to remain the leading end-user segment throughout the forecast period because of their higher procedural volumes and ability to manage complex cardiovascular cases.

North America Vascular Closure Devices Market Trends and Insights

North America is set to account for an estimated 42.8% of the global vascular closure devices market in 2026, maintaining its leadership due to the widespread adoption of minimally invasive cardiovascular procedures, advanced healthcare infrastructure, and high procedural volumes across hospitals and cardiac catheterization laboratories. The region benefits from strong reimbursement policies, favorable regulatory frameworks, and continuous technological innovation by leading medical device manufacturers.

The growing number of coronary angiography, percutaneous coronary intervention (PCI), transcatheter aortic valve replacement (TAVR), electrophysiology procedures, and peripheral vascular interventions continues to generate significant demand for vascular closure devices. Healthcare providers are increasingly adopting active closure technologies to achieve rapid hemostasis, reduce access-site complications, shorten recovery time, and support same-day discharge initiatives. In addition, increasing investments in cardiovascular research, expansion of outpatient catheterization services, and growing utilization of advanced vascular access management solutions are expected to reinforce North America's dominant position throughout the forecast period.

U.S. Vascular Closure Devices Market Trends and Insights

The U.S. is predicted to account for approximately 84.6% of the North American vascular closure devices market in 2026, making it the largest contributor to regional revenue. The country performs one of the highest volumes of coronary angiography, PCI, structural heart interventions, peripheral vascular procedures, and electrophysiology procedures globally, creating sustained demand for vascular closure devices.

Strong regulatory oversight by the U.S. Food and Drug Administration (FDA), favorable reimbursement policies, and continuous product innovation have accelerated the adoption of advanced active closure systems. Major manufacturers continue investing in clinical trials, physician education, and next-generation vascular access technologies to improve procedural outcomes. The increasing shift toward outpatient cardiovascular care, coupled with growing implementation of same-day discharge protocols, is expected to further strengthen market growth across hospitals and Ambulatory Surgical Centers (ASCs).

Canada Vascular Closure Devices Market Trends and Insights

Canada is likely to represent nearly 15.4% of the North American vascular closure devices market in 2026. The country's market is supported by expanding cardiovascular care programs, increasing adoption of minimally invasive procedures, and continued investment in modern catheterization laboratories. Rising prevalence of coronary artery disease and peripheral artery disease has increased the demand for coronary angiography and interventional cardiology procedures requiring effective vascular access closure.

Canadian hospitals are increasingly adopting vascular closure devices to reduce recovery time, improve patient comfort, and enhance procedural efficiency. Government initiatives aimed at strengthening healthcare infrastructure, along with growing awareness among physicians regarding advanced hemostasis technologies, are expected to support stable market expansion over the forecast period.

Europe Vascular Closure Devices Market Trends and Insights

Europe is forecast to hold approximately 27.4% of the global vascular closure devices market in 2026, supported by well-developed healthcare systems, increasing cardiovascular disease burden, and strong adoption of minimally invasive interventional procedures. Rising demand for coronary angiography, PCI, peripheral vascular interventions, and structural heart procedures continues to support market expansion across major European countries.

The region benefits from stringent regulatory standards, favorable reimbursement policies, and continuous technological advancements in vascular closure technologies. Hospitals are increasingly utilizing active closure devices to reduce post-procedural complications, improve catheterization laboratory efficiency, and shorten hospital stays. In addition, the growing elderly population, increasing incidence of peripheral artery disease, and expanding structural heart programs are creating sustained demand for advanced vascular access management solutions. Continued investments in cardiovascular infrastructure and physician training are expected to drive steady market growth across the region.

Germany Vascular Closure Devices Market Trends and Insights

Germany is estimated to account for approximately 24.9% of the European vascular closure devices market in 2026, supported by its highly developed healthcare infrastructure and strong network of specialized cardiovascular centers. The country performs a substantial volume of coronary angiography, PCI, electrophysiology procedures, and peripheral vascular interventions each year, driving consistent demand for vascular closure devices. Hospitals continue investing in advanced catheterization laboratory technologies to improve procedural efficiency and patient outcomes.

The growing preference for minimally invasive cardiovascular therapies, combined with increasing adoption of same-day discharge protocols, has further accelerated the utilization of active closure devices. Ongoing technological innovation and clinical research activities are expected to maintain Germany's leading position within the regional market.

UK Vascular Closure Devices Market Trends and Insights

The U.K. is forecast to capture an estimated 17.8% of the European vascular closure devices market in 2026. Increasing prevalence of cardiovascular disorders, expansion of interventional cardiology services, and growing adoption of outpatient cardiovascular procedures are supporting market growth. Hospitals across the UK are increasingly implementing rapid vascular access closure technologies to reduce patient recovery time and improve healthcare resource utilization.

The continued expansion of cardiac catheterization services, supported by investments in NHS infrastructure and modern cardiovascular care pathways, is encouraging greater adoption of vascular closure devices. Rising awareness of procedural efficiency and improved clinical outcomes is expected to sustain healthy market growth during the forecast period.

Asia Pacific Vascular Closure Devices Market Trends and Insights

Asia Pacific is expected to account for an estimated 22.1% of the global vascular closure devices market in 2026 and is projected to register the fastest growth over the forecast period. Rapid urbanization, increasing healthcare expenditure, expanding hospital infrastructure, and growing access to advanced cardiovascular care are significantly driving regional market expansion. The rising prevalence of coronary artery disease, diabetes, hypertension, and peripheral artery disease has substantially increased the number of coronary angiography, PCI, and peripheral vascular interventions performed throughout the region.

Governments across several countries are investing heavily in healthcare modernization and expanding catheterization laboratory capacity to meet the growing burden of cardiovascular diseases. Increasing participation of multinational manufacturers, strengthening domestic production capabilities, and rising physician awareness regarding advanced vascular closure technologies are expected to accelerate adoption across both developed and emerging Asian economies.

China Vascular Closure Devices Market Trends and Insights

China accounted for approximately 39.6% of the Asia Pacific vascular closure devices market in 2026, making it the region's largest revenue contributor. Rapid expansion of tertiary hospitals, continuous growth in catheterization laboratory infrastructure, and increasing cardiovascular disease prevalence are driving demand for vascular closure devices. Government initiatives focused on strengthening cardiovascular healthcare services and expanding access to minimally invasive procedures have significantly increased procedural volumes across the country. Domestic medical device manufacturers, along with collaborations between international and local companies, continue improving product availability and affordability. Ongoing investments in healthcare infrastructure and physician training are expected to support sustained market growth throughout the forecast period.

Japan Vascular Closure Devices Market Trends and Insights

Japan represented nearly 21.7% of the Asia Pacific vascular closure devices market in 2026. The country's rapidly aging population and high prevalence of cardiovascular diseases continue to drive demand for catheter-based diagnostic and therapeutic procedures. Japan's advanced healthcare infrastructure, widespread adoption of minimally invasive cardiovascular interventions, and strong clinical preference for high-quality vascular access management solutions have encouraged the use of advanced vascular closure devices. Hospitals continue investing in next-generation catheterization technologies to improve patient safety, reduce procedure-related complications, and enhance workflow efficiency. Continuous innovation, favorable reimbursement policies, and increasing procedural volumes are expected to support stable long-term market growth.

The global vascular closure devices market is moderately consolidated, with leading players such as Abbott, Medtronic, Terumo Medical, and Teleflex strengthening their presence through product innovation, collaborations, regulatory approvals, and clinical research. Companies are developing advanced devices offering faster hemostasis, improved deployment accuracy, and lower access-site complications. Emerging players, including Vivasure Medical and InSeal Medical, are introducing innovative closure technologies for complex interventions. Growing demand for TAVR, electrophysiology, and peripheral vascular procedures is further driving product innovation and competition.

Key Industry Developments:

• In June 2026, CyndRx, LLC received U.S. FDA approval for its AbsorbaSeal vascular closure device, designed for femoral arterial access site closure following catheter-based procedures, supporting the company's U.S. commercialization efforts.
• In March 2026, Haemonetics Corporation received U.S. FDA approval to expand the indication for its VASCADE MVP® XL venous vascular closure system, enabling use with larger procedural sheaths for pulsed field ablation (PFA) and left atrial appendage closure (LAAC) procedures.
• In May 2025, Zylox-Tonbridge Medical Technology received regulatory approval in Indonesia for its Zylox Unicorn Vascular Closure Device, marking the product's first international clearance and the company's entry into the Southeast Asian market.
• In July 2024, Cordis received U.S. FDA approval for its Mynx Control Venous Vascular Closure Device for 6–12 French access sites, supporting the expansion of its vascular closure device portfolio.
• In February 2024, Terumo Medical Corporation expanded its manufacturing facility in Caguas, Puerto Rico, to increase production of the Angio-Seal® Vascular Closure Device in response to growing global demand.